Abstract
The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-Bacterial Agents* / administration & dosage
-
Anti-Bacterial Agents* / pharmacokinetics
-
Anti-Bacterial Agents* / therapeutic use
-
Ceftazidime* / administration & dosage
-
Ceftazidime* / pharmacokinetics
-
Ceftazidime* / therapeutic use
-
Female
-
Fever / drug therapy*
-
Fever / microbiology
-
Humans
-
Infusions, Intravenous
-
Leukemia, Myeloid, Acute / complications
-
Leukemia, Myeloid, Acute / drug therapy*
-
Male
-
Neutropenia / complications
-
Neutropenia / drug therapy*
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / drug effects
Substances
-
Anti-Bacterial Agents
-
Ceftazidime